Português
Science Biotech and Stin Pharma announced today the launch of a 50:50 joint venture focused on the discovery and development of new drugs. Stin Pharma will benefit from access to external R&D capabilities, while Science Biotech will gain a commercial partner through the licensing of innovative products developed by the joint venture.
Under the terms of the agreement, the joint venture will focus on developing a first-in-class, breakthrough medication for the treatment of varicose veins in the lower limbs, a condition that affects millions of people in Brazil and worldwide. The new drug is expected to help reduce symptoms and slow disease progression, improving circulation and patients’ quality of life.
Science Biotech will focus on developing drugs supported by robust clinical studies and will leverage Stin Pharma’s proven commercial platform to build a unique pipeline. Upon completion of the clinical trials in the newly established joint production facility, the products will be licensed to the joint venture for registration, commercialization, and global licensing.
Initial funding for preclinical development will be provided by Science Biotech. Nortec Química S/A has been contracted for the development of the new molecule using a co-crystal design, a groundbreaking innovation that is 100% Brazilian. Clinical and commercial costs are expected to be shared equally between both companies.
The next phase will focus on developing immunomodulatory medications for the treatment of lipedema, another condition that affects a large number of women.
“We are excited about this joint venture with Stin Pharma, which brings together shared purposes, research, and technology in pursuit of more effective, accessible, and human treatments,” said Leandro Agati, CEO of Science Biotech.
Marta Perez, CEO and Chair of the Executive Committee at Stin Pharma, commented: “The creation of this joint venture will allow us to leverage our strengths, our strong medical relationships and extensive commercial expertise.”
The official launch of the new treatment is scheduled for the first half of 2026, with clinical trials beginning as soon as the formulation reaches GMP production standards.